Form 4 for SNDX Syndax Pharmaceuticals Inc
Accepted 2023-02-08 00:00:00 ET · period of report 2023-02-06 · accession 0001562180-23-001118 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-02-08 | 2023-02-06 | SNDX | Metzger Michael A | CEO, Dir | S - Sale+OE | $27.64 | -5,959 | 17.7K | -25% | -$164.7K |
| D | 2023-02-08 | 2023-02-06 | SNDX | Metzger Michael A | CEO, Dir | M - OptEx | $6.38 | +5,959 | 23.6K | +34% | +$38.0K |
| D | 2023-02-08 | 2023-02-06 | SNDX | Metzger Michael A | CEO, Dir | M - OptEx | $27.64 | -5,959 | 0 | -100% | -$164.7K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-02-06 | S | D | 5,959 | $27.64 | 17,659 | D | — | — | (F2) The sale prices ranged from $27.50 to $27.84. |
| 2 | Common | Common Stock | 2023-02-06 | M | A | 5,959 | $6.38 | 23,618 | D | — | — | |
| 3 | Derivative | Stock Options (Right to buy) | 2023-02-06 | M | D | 5,959 | $27.64 | 0 | D | $6.38 · — to 2029-02-06 | 5,959 Common Stock | (F3) This option is fully vested. |